A Potential Design Flaw of Randomized Trials of Vitamin Supplements
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
What are scientists, physicians, and the general public to make of the many null findings from randomized controlled trials (RCTs) of vitamin supplements? These trials are usually conducted on the basis of positive findings from prospective epidemiological studies and laboratory evidence of biological mechanisms. A common view is that the negative findings from the RCTs offer incontrovertible evidence that the nutrient is unrelated to disease and that the epidemiological studies are biased. An alternative explanation is that most RCTs of vitamin supplements are designed to test the hypothesis that supplementation, no matter the nutrient status, is protective. Vitamin treatment may not be effective in these trials because nutrient intake among the participants is already at optimum levels. To specify, examples are provided from the field of dementia and investigations of 3 dietary components: vitamin E, B vitamins, and docosahexaenoic acid. A basic principle of nutrition is that most nutrients have a nonlinear, inverted U-shaped association with optimum physiological function (Figure). Very low nutrient levels in diet or tissues result in poor function or even death. As the nutrient level increases, function also increases. Optimal functioning occurs over a fairly wide range of nutrient levels but at some point, higher levels become toxic and result in suboptimum function. Figure Relationship Between Level of Nutrient Status and Physiological Function Consideration of nutrient level is critically important in the assessment of the epidemiological evidence. For example, among the first 3 prospective epidemiological studies1–3 reporting on the association of dietary antioxidants and the risk of Alzheimer disease, 2 studies found inverse associations with vitamin E from food sources1,2 and 1 found no association.3 Close examination of the reported intake levels of these study populations revealed that vitamin E intake was very low in the study with null findings, and the median intake level of the highest quartile of 4.7 mg per day was in the lowest categories of intake in the other 2 studies (lowest tertile <10.5 mg/d1 and quintile median of 4.2 mg/d2). Thus, a plausible explanation for the null association is that the range of vitamin intake in this study population was below the level of protective benefit to observe an association. Nutrient levels are rarely considered in trial inclusion criteria. Further, trial volunteers are typically healthy behavior–seeking individuals and are unlikely to have low nutrient intake. More probably, intake levels are already at the level for optimal functioning (Figure, point a) and further supplementation provides no additional benefit (Figure, point b). Three RCTs examining the effect of vitamin E supplementation on cognition have been published and all have null results.4–6 Of note, none of these trials targeted individuals who had low dietary intake. Post hoc analyses reported in 2 of the trials suggested that this could have accounted for the absence of effect. In the Women’s Health Study, among women whose vitamin E consumption at baseline was less than the median intake of 6.1 mg per day, vitamin E treatment of 435 mg every other day significantly slowed the rate of cognitive decline compared with placebo (rate difference=0.05), whereas there was no effect among women whose baseline intake was greater than 6.1 mg per day (rate difference of −0.01; P value for interaction=.04).4 In a similar post hoc analysis for the Women’s Antioxidant and Cardiovascular Study (WACS), there was no significant effect of intake of 402 mg of vitamin E on alternate days among women whose baseline intake levels were less than the median of 15 mg per day, currently the recommended dietary allowance (RDA).5 This raises the question of whether 15 mg per day is already within the range of optimum cognitive health and thus too high for observing a protective effect with additional supplementation. To further complicate interpretation of these data, trial participants were allowed to take multivitamin supplements containing nutrient levels that were as high as RDA levels; thus reported baseline levels were likely higher during the course of the trial. The Women’s Antioxidant and Folic Acid Cardiovascular Study (WAFCS) also tested effects on cognition of B-vitamin supplementation, including folic acid (2.5 mg/d), vitamin B12 (1 mg/d), and vitamin B6 (50 mg/d).7 Overall, there was no effect of B-vitamin supplementation on cognitive decline but protective effects were observed among women who had dietary folate intakes of less than 279 mg per day (mean difference of 1.24 in cognitive change scores for B-vitamin treatment vs placebo compared with −0.04 among women with intakes ≥279 mg/d; P value for interaction=.002); vitamin B12 intakes less than the RDA of 2.4 μg per day (mean difference of 1.35 vs 0.10 in individuals with intakes ≥2.4 μg/d; P value for interaction
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“The exclusion criteria for these trials at best omitted persons who consumed more than 3 fish meals per week.(9,10) This is far above the level of just 1 fish meal per week observed to be inversely associated with dementia in the majority of prospective epidemiological studies.”
Durga, J., van Boxtel, M. P., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60109-3 · Cited by 758 · cited 1×
“The Folic Acid Cognitive Intervention Trial (FACIT) is a rare example of a vitamin supplement trial that targeted individuals who were found to have insufficient folate nutriture based on a stringent set of biochemical criteria.(8) Participants were randomized to receive 800 μg per day of folic acid or placebo for 3 y…”
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678
Self-citationAntioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · cited 1×
“For example, among the first 3 prospective epidemiological studies(1-3) reporting on the association of dietary antioxidants and the risk of Alzheimer disease, 2 studies found inverse associations with vitamin E from food sources(1,2) and 1 found no association.(3) Close examination of the reported intake levels of th…”
Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Albert, C. M., & Grodstein, F. (2009) · Circulation · doi:10.1161/circulationaha.108.816900 · Cited by 136
A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease
Kang, J. H., Cook, N., Manson, J., Buring, J. E., Albert, C. M., & Grodstein, F. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26404 · Cited by 114 · cited 1×
“5 mg/d), vitamin B12 (1 mg/d), and vitamin B6 (50 mg/d).(7) Overall, there was no effect of B-vitamin supplementation on cognitive decline but protective effects were observed among women who had dietary folate intakes of less than 279 mg per day (mean difference of 1.”
Cited by
Vitamin C: The known and the unknown and Goldilocks
Padayatty, S., & Levine, M. (2016) · Oral Diseases · doi:10.1111/odi.12446 · Cited by 753
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
“Unfortunately, most randomized clinical trials of dietary supplements have not targeted populations with low nutrient status, and trial results have been null overall [246].”
BackgroundSelf-citationHomocysteine, B Vitamins, and Cognitive Impairment
Smith, A. D., & Refsum, H. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050947 · Cited by 513
Diet and Inflammation in Cognitive Ageing and Alzheimer’s Disease
McGrattan, A. M., McGuinness, B., McKinley, M. C., Kee, F., Passmore, P., Woodside, J. V., & McEvoy, C. T. (2019) · Current Nutrition Reports · doi:10.1007/s13668-019-0271-4 · Cited by 385
Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications
Apostolova, N., & Victor, V. M. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5952 · Cited by 299
Metadata
- Authors
- Morris, M. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-04-06
- Volume
- 305
- Issue
- 13
- Pages
- 1348
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1991254279
- Cited by
- 117
- References
- 8
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.